Share on StockTwits

Relypsa (NASDAQ:RLYP) major shareholder 5Am Partners Ii, Llc sold 433,000 shares of the stock on the open market in a transaction dated Tuesday, August 26th. The stock was sold at an average price of $26.51, for a total transaction of $11,478,830.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Separately, analysts at Stifel Nicolaus raised their price target on shares of Relypsa from $45.00 to $47.00 in a research note on Tuesday, August 12th. They now have a “buy” rating on the stock. Eight research analysts have rated the stock with a buy rating, Relypsa currently has an average rating of “Buy” and an average target price of $48.50.

Shares of Relypsa (NASDAQ:RLYP) traded down 2.83% on Wednesday, hitting $25.77. 193,614 shares of the company’s stock traded hands. Relypsa has a one year low of $11.55 and a one year high of $52.74. The stock has a 50-day moving average of $24.59 and a 200-day moving average of $28.0. The company’s market cap is $876.1 million.

Relypsa (NASDAQ:RLYP) last released its earnings data on Monday, August 11th. The company reported ($0.51) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.06. Analysts expect that Relypsa will post $-2.47 EPS for the current fiscal year.

Relypsa, Inc is a pharmaceutical company focused on the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular and metabolic diseases.

Receive News & Ratings for Relypsa Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relypsa Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.